The Technical Analyst
Select Language :
Mediwound Ltd [MDWD]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology

Mediwound Ltd Price, Forecast, Insider, Ratings, Fundamentals & Signals

Mediwound Ltd is listed at the  Exchange

-5.63% $14.25

America/New_York / 28 mar 2024 @ 16:00


FUNDAMENTALS
MarketCap: 135.26 mill
EPS: -0.750
P/E: -19.00
Earnings Date: May 27, 2024
SharesOutstanding: 9.49 mill
Avg Daily Volume: 0.0615 mill
RATING 2024-03-28
B-
Neutral
RATINGS
Rating CashFlow: Strong Sell
Return On Equity: Sell
Return On Asset: Neutral
DE: Buy
P/E: Strong Sell
Price To Book: Buy
QUARTER GROWTHS
3/224/221/232/233/234/23
Revenue
Gr.Profit
Ebit
Asset
Debt
PE RATIO: COMPANY / SECTOR
0.00x
Company: PE -19.00 | sector: PE -3.05
PE RATIO: COMPANY / INDUSTRY
-3.23x
Company: PE -19.00 | industry: PE 5.88
DISCOUNTED CASH FLOW VALUE
$-6.13
(-143.01%) $-20.38
Date: 2024-03-29
Expected Trading Range (DAY)

$ 13.59 - 14.92

( +/- 4.67%)
ATR Model: 14 days

Forecast: 16:00 - $14.31

Live Trading Signals (every 1 min)

Forecast 1: 16:00 - $14.31
Forecast 2: 16:00 - $14.31
Forecast 3: 16:00 - $14.31
SCORE
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Indicator Signals
RSI 21
SMA
Trend
Trend 2
Trend 3
MACD
Volume Signals
Price $14.25 (-5.63% )
Volume 0.175 mill
Avg. Vol. 0.0615 mill
% of Avg. Vol 284.75 %
Signal 1:
Signal 2:

Today

Intraday chart data with high, low, open and close for Mediwound Ltd

Last 12 Months

Last 12 months chart data with high, low, open and close for Mediwound Ltd

RSI

Intraday RSI14 chart for Mediwound Ltd

Last 10 Buy & Sell Signals For MDWD

0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%

Avg return buy: 0.00 % | Avg return sell: 0.00 %

$1 invested is now $1.00 or 0.00% since Coming Soon

Date Signal @ Closed %
Profile picture for
            Mediwound Ltd

MDWD

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.

Last 10 Buy Signals

Date Signal @
PEPECOINUSDMar 29 - 07:545.90
NXMUSDMar 29 - 07:5072.32
GNSUSDMar 29 - 07:545.06
BGBUSDMar 29 - 07:541.005
BUSDUSDMar 29 - 07:541.001
ONTUSDMar 29 - 07:52$0.369
FOLDUSDMar 29 - 07:5026.93
CFXUSDMar 29 - 07:49$0.478
FISUSDMar 29 - 07:510.980
MUSEUSDMar 29 - 07:4818.73

Latest Press Releases

Latest News

Disclaimer:

"JimStromberg.com" is a research service that provides financial data and technical analysis of publicly traded stocks. All users should speak with their financial advisor before buying or selling any securities. Users should not base their investment decision upon "JimStromberg.com". By using the site you agree and are held liable for your own investment decisions and agree to Terms of Use and Privacy Policy. Please read the full disclaimer here.